Dysregulation of epicardial adipose tissue in cachexia due to heart failure: the role of natriuretic peptides and cardiolipin

Petra Janovska1, Vojtech Melenovsky1*, Michaela Svobodova2, Tereza Havlena1, Helena Kratochvilova1, Martin Haluzik1, Eva Hoskova1, Terezie Pelikanova1, Josef Kautzner1, Luca Monzo1, Ivana Jurcova1, Katerina Adamcova2, Lucie Lenkova2, Jana Buresova2, Martin Rossmeisl1, Ondrej Kuda2, Tomas Cajka2 & Jan Kopecky3*

1Department of Cardiology, Institute for Clinical and Experimental Medicine - IKEM, Prague, Czech Republic, 2Institute of Physiology of the Czech Academy of SciencesPrague 4, Czech Republic

Abstract

Background  Cachexia worsens long-term prognosis of patients with heart failure (HF). Effective treatment of cachexia is missing. We seek to characterize mechanisms of cachexia in adipose tissue, which could serve as novel targets for the treatment.

Methods  The study was conducted in advanced HF patients (n = 52; 83% male patients) undergoing heart transplantation. Patients with ≥7.5% non-intentional body weight (BW) loss during the last 6 months were rated cachectic. Clinical characteristics and circulating markers were compared between cachectic (n = 17) and the remaining, BW-stable patients. In epicardial adipose tissue (EAT), expression of selected genes was evaluated, and a combined metabolomic/lipidomic analysis was performed to assess (i) the role of adipose tissue metabolism in the development of cachexia and (ii) potential impact of cachexia-associated changes on EAT-myocardium environment.

Results  Cachectic vs. BW-stable patients had higher plasma levels of natriuretic peptide B (BNP; 2007 ± 1229 vs. 1411 ± 1272 pg/mL; P = 0.010) and lower EAT thickness (2.1 ± 0.8 vs. 2.9 ± 1.4 mm; P = 0.010), and they were treated with ≥2.5-fold lower dose of both β-blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACE/ARB-inhibitors). The overall pattern of EAT gene expression suggested simultaneous activation of lipolysis and lipogenesis in cachexia. Lower ratio between expression levels of natriuretic peptide receptors C and A was observed in cachectic vs. BW-stable patients (0.47 vs. 1.30), supporting activation of EAT lipolysis by natriuretic peptides. Fundamental differences in metabolome/lipidome between BW-stable and cachectic patients were found. Mitochondrial phospholipid cardiolipin (CL), specifically the least abundant CL 70:6 species (containing C16:1, C18:1, and C18:2 acyls), was the most discriminating analyte (partial least squares discriminant analysis; variable importance in projection score = 4). Its EAT levels were higher in cachectic vs. BW-stable patients and correlated with the degree of BW loss during the last 6 months (r = −0.94; P = 0.036).

Conclusions  Our results suggest that (i) BNP signalling contributes to changes in EAT metabolism in cardiac cachexia and (ii) maintenance of stable BW and ‘healthy’ EAT-myocardium microenvironment depends on the ability to tolerate higher doses of both ACE/ARB inhibitors and β-adrenergic blockers. In line with preclinical studies, we show for the first time in humans the association of cachexia with increased adipose tissue levels of CL. Specifically, CL 70:6 could precipitate wasting of adipose tissue, and thus, it could represent a therapeutic target to ameliorate cachexia.

Keywords  Heart failure; Lipolysis; Natriuretic peptides; Adipose tissue; Cardiolipin; Cardiac cachexia
Introduction

Despite the fact that obesity is a strong risk factor for heart failure (HF) in the general population, obese patients with already established HF have better long-term prognosis than their non-obese counterparts, a situation sometimes referred to as ‘an obesity paradox’.1–3 In patients with advanced HF, fat mass seems to be associated with better survival2,4 while non-intentional weight loss, the defining feature of cardiac cachexia,3,5–7 is a strong independent risk factor for mortality from HF.1,3 Other chronic conditions such as cancer or chronic obstructive pulmonary disease often also lead to cachexia, which compromises treatment options and survival.8 Thus, distinct diseases may trigger a final common mechanism that leads to chronic body wasting and promotes other organ dysfunctions. Importantly, cachexia could not be reversed using conventional nutritional support, and effective mechanism-based treatment of cachexia needs to be developed.8

Disturbed energy handling in adipose tissue represents an early event in the development of cancer cachexia,6–10 but the role of metabolic, immune, and secretory alterations of adipose tissue in the development and/or progression of cardiovascular diseases (including HF) is poorly understood.11–13 In particular, epicardial adipose tissue (EAT) was in the focus of very few studies.12–14 Due to its close proximity and shared microvascular network, the EAT-myocardium microenvironment can be a place of intensive exchange of paracrine regulators or metabolic substrates, and it may serve as a transducer of systemic metabolic state, inflammation, or neurohumoral activation on the cardiac muscle.15,16

Fatty acids released from adipose tissue are crucial for cardiac function, because a majority of cardiac ATP comes from fatty acid β-oxidation and oxidative phosphorylation in mitochondria.17 Activation of fatty acid mobilization is common in advanced stages of HF, due to enhanced adipose tissue lipolysis.11 Lipolysis is activated in HF due to activation of the sympathetic nervous system, renin-angiotensin-aldosterone system (RAAS)17–20 and elevated circulating levels of natriuretic peptides A and B (ANP and BNP)11,18 that are secreted directly by the heart.19,21 Adipose tissue inflammation and insulin resistance further contribute to altered adipose tissue metabolism in HF patients.8,17 In advanced HF, excessive fatty acid mobilization leads to a switch in substrate utilization by the myocardium, from β-oxidation to energetically less effective glycolysis,17,22 and eventually to oxidation of ketone bodies.22

In order to identify potential therapeutic targets to reduce body wasting and improve HF outcomes, we conducted a study that compared clinical characteristics, circulating markers, and notably, EAT gene expression and metabolome in advanced HF patients with or without cardiac cachexia.

Materials and methods

Study cohort

Study cohort (n = 52) consisted of consecutive patients with end-stage HF who underwent heart transplantation at the Institute for Clinical and Experimental Medicine (IKEM) in Prague, Czech Republic. Subjects with body weight (BW)-reducing therapy or endocrine disease were excluded. Samples of EAT from the HF patients were harvested from the anterior interventricular groove immediately after explantation of the heart and were placed into liquid nitrogen and stored at −80°C until analysis. BW-trajectories during the last 6 months before transplantation were obtained by direct questioning and from medical records. Cachexia was defined as non-intentional non-edematous BW loss of at least 7.5% during the previous 6 months, as compared with BW-stable patients.3 This relatively high cut-off (other studies3, 5–7) was used in order to maximally unmask the impact of BW-wasting on various parameters analysed using a relatively small patient’s cohort (Discussion).

Medical records were queried to obtain clinical history, echocardiographic, and haemodynamic examinations obtained before heart transplantation. The daily dose of β-adrenergic blockers was converted to equivalents dose of metoprolol (mg/day) using ratios of guidelines-recommended target doses (Table 7.2 in Ponikowski et al.6). In similar way, daily dose of RAAS activity inhibitors, namely angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB), was converted to equivalent dose of ramipril (mg/day). None of the patients was treated by sacubitril/valsartan. The protocol was approved by the Ethics Committee of IKEM. All the patients signed informed consent approving their enrolment in the study and research analysis of the EAT and blood samples.

Epicardial adipose tissue gene expression

Analysis was performed using total RNA isolated from the tissue and quantitative real-time PCR. Results were normalized to geometric mean of three housekeeping genes: GAPDH, HPRT, and PPIA. For gene names, PCR primers and other details, see Supporting Information, Table S1.
Blood tests

Serum and plasma samples were stored at −80°C. Routine biochemical parameters were evaluated using an automated Abbott Architect ci1600 analyser. BNP concentrations were measured using a microparticle immunoassay (Architect BNP; Abbott Laboratories). Insulin was measured using RIA (Beckman Coulter).

Metabolomic and lipidomic analysis

A combined targeted and untargeted workflow for the metabolome, lipidome and exposome characterization was performed using EAT extracts (Supporting Information, Method S1).

Statistical analyses

The data are presented as means ± standard error or means ± standard deviation, as indicated. Comparisons were analysed using Student’s t-test, and considered significant when P ≤ 0.05. Spearman’s rank correlation coefficients and linear regression were used to evaluate correlations between various parameters. To find fundamental relations between data sets, partial least squares discriminant analysis was performed using MetaboAnalyst 4.0 web portal.23

Results

Clinical characteristics

The baseline characteristics of the patients are summarized in Table 1. The cohort consisted of predominantly middle-aged males, with prevailing non-ischemic HF aetiology. Twelve patients (23%) were treated for type 2 diabetes, 22 (42%) were overweight, and 6 (12%) were obese [body mass index (BMI) > 30 kg·m⁻²]. Seventeen patients (33%) reported significant (≥7.5%) non-intentional BW loss during the last 6 months—the defining feature of cardiac cachexia,4 which

Table 1 Clinical variables and medication

| Variable                                | All patients | BW-stable | Cachexia | P value |
|-----------------------------------------|--------------|-----------|----------|---------|
|                                         | n = 52       | n = 35    | n = 17   |         |
| Age (years)                             | 54 ± 11      | 55 ± 10   | 52 ± 14  | 0.725   |
| Gender (M; %)                           | 83           | 86        | 76       | 0.409   |
| Body mass index (kg/m²)                 | 25 ± 4       | 26 ± 4    | 22 ± 3   | <0.001  |
| Body weight (BW) change (%)             | −4.8 ± 6.1   | −1.3 ± 3.3| −11.9 ± 4.1| <0.001 |
| NYHA class (1–4)                        | 3.4 ± 0.5    | 3.3 ± 0.5 | 3.6 ± 0.5| 0.031   |
| Non-ischemic HF (%)                     | 65           | 57        | 82       | 0.073   |
| HF duration (years)                     | 5.2 ± 4.1    | 5.4 ± 3.9 | 4.7 ± 4.4| 0.556   |
| Inotrope therapy (prior Tx; %)          | 21           | 14        | 35       | 0.082   |
| Atrial fibrillation on ECG (%)          | 30           | 28        | 32       | 0.499   |
| Echocardiography                        |              |           |          |         |
| LV ejection fraction (%)                | 21 ± 6       | 21 ± 7    | 19 ± 5   | 0.302   |
| LV end-diastolic diameter (mm)          | 74 ± 10      | 72 ± 9    | 73 ± 12  | 0.794   |
| Mitral regurgitation (0–4)              | 2.4 ± 1.1    | 2.3 ± 1.1 | 2.6 ± 1.1| 0.307   |
| Left atrial volume index (ml/m²)        | 74 ± 30      | 69 ± 29   | 79 ± 32  | 0.220   |
| Right atrial area (cm²)                 | 25 ± 8       | 25 ± 7    | 26 ± 9   | 0.904   |
| Tricuspid regurgitation (grade 0–4)     | 2.1 ± 0.9    | 2.0 ± 1.0 | 2.1 ± 0.9| 0.751   |
| RV diastolic diameter (mm)              | 46 ± 8       | 45 ± 8    | 47 ± 9   | 0.407   |
| RV dysfunction grade (0–4)              | 1.6 ± 1.0    | 1.7 ± 1.0 | 1.4 ± 0.9| 0.403   |
| TAPSE (mm)                              | 14 ± 5       | 14 ± 5    | 14 ± 4   | 0.736   |
| Epicardial fat thickness (mm)           | 2.6 ± 1.3    | 2.9 ± 1.4 | 2.1 ± 0.8| 0.010   |
| Haemodynamics                           |              |           |          |         |
| Heart rate (b.p.m.)                     | 77 ± 13      | 77 ± 13   | 77 ± 13  | 0.710   |
| Mean blood pressure (mmHg)              | 85 ± 10      | 88 ± 10   | 79 ± 7   | 0.130   |
| Cardiac output (L/min)                  | 3.5 ± 0.8    | 3.7 ± 0.7 | 3.2 ± 1.0| 0.131   |
| Right atrial pressure (mmHg)            | 9.4 ± 4.4    | 10.1 ± 4.9| 8.1 ± 3.4| 0.043   |
| PA mean pressure (mmHg)                 | 33 ± 9       | 34 ± 10   | 32 ± 8   | 0.384   |
| PA wedge pressure (mmHg)                | 24 ± 8       | 24 ± 8    | 23 ± 7   | 0.563   |
| Medication                              |              |           |          |         |
| Furosemide (mg/day)                     | 168 ± 164    | 155 ± 125 | 193 ± 226| 0.534   |
| *β-blockers (mg/day)                    | 40 ± 50      | 50 ± 56   | 20 ± 25  | 0.011   |
| *ACE/ARB-inhibitors (mg/day)            | 1.4 ± 2.0    | 1.7 ± 2.1 | 0.7 ± 1.3| 0.035   |

*β-blockers, dose in metoprolol equivalents, ACE/ARB-inhibitors, dose of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in ramipril equivalents (Materials and methods); LV, left ventricular, RV, right ventricle; NYHA, New York Heart Association functional class; TAPSE, tricuspid annular plane systolic excursion; Tx, transplantation; PA, pulmonary artery.

Data are shown for all the patients, or two subgroups of the patients split based on their BW trajectories during the previous 6 months (BW-stable vs. Cachexia). Data are means ± SD. Bold, statistical significant difference.

Eight out of 52 patients received neither β-blockers nor ACE/ARB-inhibitors, and 34 patients received a combination of the two.
discriminated them from BW-stable patients (n = 35; 67%). Cachectic patients were more symptomatic, had higher New York Heart Association class and ~1.4-fold lower EAT thickness, and tended to have lower systemic blood pressure and cardiac output. Cachectic patients had more often non-ischemic HF aetiology and were treated with ~2.5-fold lower dose of β-blockers and ~2.4-fold lower dose of ACE/ARB inhibitors as compared with BW-stable patients. Cachectic vs. BW-stable HF-patients displayed ~1.4-fold higher BNP plasma levels reflecting the higher myocardial stress, despite there was no significant difference in cardiac structure by echocardiography. Levels of plasma glucose tended to be lower, and that of haemoglobin A1C were lower in the cachecic patients (Table 2).

**The impact of cachexia on epicardial adipose tissue expression of lipid metabolism, adipokines, and inflammatory genes**

To characterize the role of adipose tissue immunometabolism in cachexia development, expression of selected genes in EAT was evaluated and compared between BW-stable and cachectic patients (Figure 1A–D; for fold change of the mean values, Supporting Information, Table S2). Concerning lipolysis (Figure 1A), expression of lipolysis-promoting natriuretic peptide receptor A (NPRA) gene was similar in both groups (for gene names, see Table S1). Mean expression of natriuretic peptide receptor C (NPRC, also called clearance receptor) gene was ~2.4 higher in BW-stable patients. Lower NPRC/NPRA transcript level ratio in cachectic vs. BW-stable patients (0.47 vs. 1.30; Table S2) suggested lower clearance of natriuretic peptides resulting in stimulation of lipolysis. Accordingly, both NPRC expression and NPRC/NPRA transcript level ratio correlated negatively with systemic levels of BNP, positively with BMI and BW change, daily dose of both β-blockers and ACE/ARB-inhibitors, and mean blood pressure (Figure 2). Genes for both PTGDS and ADORA1 tended to be up-regulated in association with cachexia (Figure 1A), suggesting increased production of prostaglandin D2 that exerted antilipolytic effect, in concert with ADORA1 stimulation. In spite of the up-regulation of PTGDS and ADORA1, genes for (i) the key lipases ATGL and HSL, (ii) PLIN1, which is required for activation of lipolysis, (iii) cell death-inducing DNA fragmentation factor (CIDEA), which counteracts inhibition of lipolysis by AMP-activated protein kinase, and (iv) zinc-c2-glycoprotein, the lipolytic factor known to be induced in cancer cachexia, tended to be up-regulated in cachectic patients (Figure 1A). With respect to genes engaged in triacylglycerols formation (Figure 1B), we focused on (i) FAS, which is essential for de novo lipogenesis, (ii) PEPCK, required for glycogenoneogenesis, (iii) DGAT1 and DGAT2, engaged in fatty acid re-esterification/triacylglycerol synthesis, and (iv) FABP1, fatty acid transporter. Mean expression of FAS, and DGAT1 was ~2.9-fold and ~1.6-fold higher in cachetic than BW-stable patients, respectively. Also, expression of PEPCK, DGAT2, and FABP1 tended to be up-regulated in cachexia. Next, we focused on expression of genes engaged in control of lipid catabolism and mitochondrial functions (Figure 1C). These genes

| Parameter | Control range | All patients | BW-stable | Cachexia | P value |
|-----------|---------------|-------------|-----------|----------|---------|
| Fasting plasma glucose (mmol/L) | 3.6–5.6 | 5.8 ± 1.2 | 6 ± 1.3 | 5.4 ± 1.1 | 0.112 |
| Fasting plasma insulin (μIU/mL) | 4.1 ± 3.8 | 4.2 ± 4.1 | 3.9 ± 3.1 | 0.846 |
| HOMA-IR | 1.0 ± 1.0 | 1.1 ± 1.1 | 0.9 ± 0.7 | 0.492 |
| Haemoglobin A1C (mmol/mol) | 20–42 | 49 ± 10 | 50 ± 12 | 44 ± 6 | 0.017 |
| Bilirubin (μmol/L) | 3–20 | 21 ± 11 | 21 ± 12 | 23 ± 11 | 0.584 |
| Sodium (mmol/L) | 137–144 | 135 ± 4 | 136 ± 4 | 134 ± 5 | 0.321 |
| Potassium (mmol/L) | 3.5–5.1 | 4.1 ± 0.6 | 4.1 ± 0.7 | 4.2 ± 0.4 | 0.219 |

Data are shown for all the patients, or two subgroups of the patients split based on BW trajectories during the previous 6 months (BW-stable vs. Cachexia). Data are means ± SD. Bold, statistical significant difference.

“Median (Q1–Q3) for BNP: all patients, 1283 (599–2413); BW-stable, 707 (445–1815); Cachexia 1650 (902–2506).

“Control (normal) range at the IKEM Central Laboratory; data are for both genders, only the BNP data are for man at 55–65 years of age, for women of this age: 10–155 pg BNP/ml plasma. HOMA, homeostasis model assessment;

For log-transformed data.
FIGURE 1 Expression of lipid metabolism, adipokines and inflammatory genes in epicardial adipose tissue. Comparison between body weight-stable \((n = 35)\) and cachectic \((n = 17)\) patients. (A–D) Transcripts grouped according to their functions. Transcript levels \((A.U.)\) were normalized (i) to geometric mean of three housekeeping genes and (ii) by cube root transformation. Data are means ± SE; Student’s t-test. *Significant difference between the groups; for fold-change of the means, see Table S2. For gene names abbreviations, see the main text and Table S1.

FIGURE 2 Correlation of gene expression markers of natriuretic peptide system activity with clinical parameters. Linear regression plot of the relationship between transcript levels of NPRC (upper panels), or the ratio between NPRC and NPRA transcript levels \((\text{NPRC/NPRA})\); lower panels), and the indicated parameters. Linear regression lines, including 95% confidence intervals, are shown. Spearman’s rank correlation coefficients \((r)\) and \(P\) value (indicated in the figures) were also calculated to assess the correlations between various parameters. For the source data, see Figure 1 and Tables S1, 1, and 2. ACE/ARB inhibitors, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; BNP, natriuretic peptides B; BMI, body mass index; BW, body weight; NPRC, natriuretic peptide receptor C.
included (i) PPARα, which acts both as a sensor for fatty acids and ligand-activated transcription factor enhancing lipid metabolism, (ii) PPARγ, and its target PGC-1α inducing mitochondrial biogenesis, (iii) PDK4, which limits glucose oxidation by inhibiting pyruvate dehydrogenase and thus supports β-oxidation, and (iv) ACSL1 and ACADL, which are engaged in mitochondrial β-oxidation of fatty acids. Expression of all these genes tended to be up-regulated in cachexia (Figure 1C). Regarding the secretory functions and immune status of EAT (Figure 1D), we focused on the expression of genes for adiponectin (ADIPOQ) and leptin (LEP), representing two major adipokines, as well as pro-inflammatory TNFα gene. Expression of none of these genes was significantly affected by cachexia.

Although ionotropic support tended to be higher in cachectic patients prior the surgery (35% vs. 14%, Table 1), it had no impact on the expression of lipid metabolism, adipokines, and inflammatory genes in EAT (not shown). Relatively small differences in the gene expression pattern between BW-stable and cachectic patients prompted us to explore the data by using a complex pathway analysis of EAT metabolism (Figure 3). All the differences in mean expression of the individual genes between BW-stable and cachectic patients were considered, irrespective of their statistical significance (Table S2). This approach revealed a broad induction of EAT lipid metabolism in cachexia. It can be assumed that adipose tissue wasting in cachexia is caused by a net loss of tissue triacylglycerols, which are stored in adipocytes. This implies higher stimulation of lipolytic and oxidative pathways activities, which lead to decrease in the intracellular triacylglycerol pool as compared with insufficient stimulation of glyceroneogenesis, de novo fatty acid synthesis and fatty acid re-esterification/triacylglycerol synthesis that are engaged in the replenishment of the pool.

**Global impact of cachexia on epicardial adipose tissue metabolome**

To get further insight into the mechanisms underlying the role of adipose tissue in the development of cardiac cachexia, we performed untargeted metabolomic and lipidomic analysis of EAT. Using six different gas chromatography–mass spectrometry platforms (Method S1), we annotated 750 compounds including polar metabolites, complex lipids, and various exposome compounds such as drugs (Supporting Information, Figure S1 and Dataset S1). All known from these analytes, except for drugs and other non-physiological analytes, that is the exposome compounds (n = 47; Supporting Information, Table S3), were used for further analysis.

Using partial least squares discriminant analysis, a supervised classification method, a separation between BW-stable and cachectic patients, was observed indicating a fundamental difference between the two groups (Figure 4A). Variable importance in projection (VIP) identified the most discriminating analytes. Among the top 30 VIP analytes (Figure 4B), various (lyso)phospholipids represented a majority (60%), while triacylglycerols together with diacylglycerols were the second (13%) and ceramides the third (10%) most abundant classes among the discriminating analytes. However, cardiolipin (CL) 7:0:6 was clearly the single most important discriminating analyte. These results indicate that development of cachexia in HF-patients is linked with major changes in EAT metabolome and suggest an involvement of at least some of the VIP analytes in the mechanisms underlying pathological wasting of adipose tissue. Indeed, in preclinical studies, increase of CL levels in various tissues was causally linked to cancer cachexia. Therefore, CL in EAT of the HF-patients became the major focus of the next part of our study.

Involvement of epicardial adipose tissue cardiolipin in cachexia

Evaluation of the lipomics data revealed presence of four different CLs in EAT, namely CL 7:0:6, CL 7:0:7, CL 7:2:7, and CL 7:2:8 (Figure 5A). Side chains of these CLs contained combinations of three different acyls, namely palmitoleic (C16:1), oleic (C18:1), and linoleic (C18:2) acid (Supporting Information, Table S4). Only CL 7:0:6 discriminated between BW-stable and cachectic patients, while it represented the least abundant CL species (Figure 5A). Its levels were ~1.5-fold higher in the cachetic patient’s group (Table S4). EAT metabolome also contained several phosphatidylglycerol (PG) species, that is the building blocks in the synthesis of CL (Figure 5B). Levels of most of these PGs tended to be higher in cachetic as compared with BW-stable patients (Table S4).

Importantly, EAT levels of CL 7:0:6 significantly correlated with BW markers, that is negatively with both BMI and BW change. Similar trends were observed with CL 7:0:7. No correlation between the BW markers and the levels of either CL 7:2:7 or CL 7:2:8 was observed (Figure 5C). Thus, the strength of the association between various CLs and the degree of cachexia increased in the case of less abundant CL species (Figure 5A).

Hierarchical clustering of EAT analytes using only levels of the four CLs revealed two clusters of patients at the first level of hierarchy, Cluster A4 and Cluster B4, respectively (Figures S5D). Cluster A4 (13 cases) was composed exclusively of BW-stable patients. Cluster B4 (39 cases) represented a heterogeneous mixture of BW-stable (56%) and cachectic (44%) patients. EAT levels of most CLs and PGs were higher in Cluster B4-patients, with CL 7:0:6 showing the largest (~47-fold) difference (Table S4). In agreement with the comparison between BW-stable and cachectic patients (Tables 1

Journal of Cachexia, Sarcopenia and Muscle 2020
DOI: 10.1002/jcsm.12631
and 2), the homogenous group of BW-stable patients in Cluster A4 exhibited lower plasma BNP levels and higher dose of both β-blockers and ACE/ARB-inhibitors as compared with Cluster B4-patients (Supporting Information, Table S5).

At the gene expression level, Cluster A4 patients showed relatively high NPRC and relatively low ADORA1 and FAS expression, consistent with the difference in gene expression pattern between BW-stable and cachectic patients (Table S2). Also minor differences in expression of the other genes between Cluster A4 and Cluster B4 patients were mostly in agreement with the corresponding differences between BW-stable and cachectic patients; in addition, the Cluster A4 vs. Cluster B4 comparison unmasked higher expression of leptin gene in Cluster A4, that is in BW-stable patients (Table S2).

The above results documented the role of CL with a specific acyl side chains composition, namely the CL 70:6 containing C16:1, C18:1, and C18:2 acyls, in the development of cardiac cachexia. Therefore, we aimed to ascertain the mechanisms underlying the differential control of EAT levels of various CLs in cachexia. First, we focused on potential role of mechanisms underlying the differential control of EAT levels of various CLs in cachexia. Therefore, we aimed to ascertain the mechanisms underlying the differential control of EAT levels of various CLs in cachexia. Therefore, we aimed to ascertain the mechanisms underlying the differential control of EAT levels of various CLs in cachexia. Therefore, we aimed to ascertain the mechanisms underlying the differential control of EAT levels of various CLs in cachexia. Therefore, we aimed to ascertain the mechanisms underlying the differential control of EAT levels of various CLs in cachexia. Therefore, we aimed to ascertain the mechanisms underlying the differential control of EAT levels of various CLs in cachexia. Therefore, we aimed to ascertain the mechanisms underlying the differential control of EAT levels of various CLs in cachexia. Therefore, we aimed to ascertain the mechanisms underlying the differential control of EAT levels of various CLs in cachexia. Therefore, we aimed to ascertain the mechanisms underlying the differential control of EAT levels of various CLs in cachexia. Therefore, we aimed to ascertain the mechanisms underlying the differential control of EAT levels of various CLs in cachexia.
correlations between the levels of either CL 70:6 or CL 70:7 and most PGs were found. For CL 72:7 or CL 72:8 species, the correlations were less frequent (Figure S2).

Secondly, we focused on the role of genes engaged in CL synthesis, PG synthase 1 (PGS1) and CL synthase 1 (CRLS1), and in remodelling of the acyl side chains of CL, acyl-CoA ∶ lysocardiolipin acyltransferase 1 (LCLAT1). Expression of these genes was compared between BW-stable and cachectic patients, as well as between Cluster A and Cluster B4 patients (Figure 6 and Supporting Information, Table S6). With PGS1 and LCLAT1, no significant differences between the groups were observed. However, CRLS1 expression was significantly higher (∼1.7-fold) in Cluster B4 as compared with Cluster A4 patients, while expression of both PGS1 and LCLAT1 showed a similar trend.

These results suggested that differential increase in the EAT levels of various CLs in cachexia could reflect both (i) basal levels of PGs that are used for CL synthesis and (ii) activity of the genes engaged in CL synthesis and remodelling.

**Discussion**

To our knowledge, this is the first study focused on the role of EAT-myocardium microenvironment in the development of cardiac cachexia. A complex approach was used, which was based on the characterization of both metabolome/lipidome and gene expression in EAT of the end-stage HF-patients with and without cardiac cachexia.

For the characterization of the impact of BW-wasting on various parameters in our study, the BW-stable and cachectic patients were discriminated using a non-edematous BW loss of at least 7.5% during the previous 6 months. This 7.5% cut-off, used also to define cardiac cachexia by Anker and colleagues in 1997, was higher as compared with that of 5% used in the 2008 cardiac cachexia definition or the 6% cut-off point in the ESC Guidelines from 2016; Anker et al. When we have analysed the data at several cut-off points, equal to 5%, 6%, and 7.5% (not shown), we have found that the highest cut-off (7.5%) helped to uncover subtle links between the BW-loss and EAT gene expression (Figure 1), while the differences between BW-stable and cachectic patients (i) in the clinical variables and medication (Table 1) or plasma parameters (Table 2) and (ii) metabolome/lipidome (Figures 4 and 5D) were only marginally affected by various cut-off points. Thus, due to limited number of studied subjects, we choose the higher cut-off point of BW change to enhance the contrast between cachectic and BW-stable patients.

Our results demonstrate fundamental differences in metabolome/lipidome between BW-stable and cachectic patients. CL, a phospholipid of the inner mitochondrial membrane, specifically CL 70:6, was the most discriminating analyte. In preclinical models of cancer cachexia, intracellular
accumulation of CL led to increased energy-wasting due to the uncoupling of mitochondrial oxidative phosphorylation.\textsuperscript{10,30–32} This occurred in several tissues, including white fat, which became involved early during cachexia development.\textsuperscript{10} We demonstrate here for the first time in humans increased tissue levels of CLs in cachexia.

Based on the results of the animal study,\textsuperscript{10} changes observed in EAT levels of CLs probably occurred also in other fat depots and other tissues of the cachectic patients. However, CL-induced modulation of EAT metabolism could be of special
 means ± SE; Student’s t-test. *Significant difference between the groups. For gene names abbreviations, see the main text and Table S1.

FIGURE 6 Expression of genes engaged in synthesis (PGS1 and CRLS1) and remodelling (LCLAT1) of cardiolipin across patient’s subgroups. Transcript levels (A.U.) were normalized to geometric mean of three housekeeping genes. Data (Table S6) for all patients (n = 52), or the following subgroups: (i) BW-stable (n = 35) and cachectic (n = 17) patients; and (ii) Clusters A and B4 patients (n = 13 and n = 39, respectively), are shown. Data are means ± SE; Student’s t-test. *Significant difference between the groups. For gene names abbreviations, see the main text and Table S1.

importance for heart function due to the mutual interactions within the EAT-myocardium environment (Introduction).

Our results suggest that CL of a specific acyl profile could be causally involved in cachexia. Side chains of the four CLs contained in EAT represented combinations of only three different acyls, namely C16:1, C18:1, and C18:2, with the CL species abundance increasing with larger molecular mass and a higher degree of unsaturation and length of the acyl side chains (Table S4). It was not the major CL species, that is CL 72:8 (tetralinoleoyl-CL), which is normally present in insulin-sensitive tissues, but the least abundant CL 70:6, which discriminated between BW-stable and cachetic patients. As suggested by the results of the animal study, CL70:6 could induce the uncoupling of oxidative phosphorylation in EAT mitochondria of cachetic patients. Its specific molecular acyl composition could underlie this effect.

Indeed, the changes in the tissue content of specific CL species and or changes in the acyl profile of CL could be the cause of specific pathologies: (i) Barth syndrome, a multisystem disorder characterized by cardiomyopathy, is associated with reduced levels of CL 72:8 (tetralinoleoyl-CL) in mitochondria, due to the defect of CL transacylase tafazzin, (ii) decrease of CL 72:8 preceded the development of HF in spontaneously hypertensive rats and correlated with a loss of mitochondrial cytochrome oxidase activity (reviewed in Saini-Chohan et al.34), and (iii) replacement of C18:2 by docosahexaenoic acid (C22:6) in the CL side chains leads to mitochondrial dysfunction in diabetes and other metabolic diseases.35 The mechanism of induction of CLs tissue levels in cachexia has yet to be characterized in detail. Our results in EAT of HF-patients show a link to increased tissue levels of PGs, the building blocks in the synthesis of CLs, suggesting an involvement of the enzymes engaged in CL synthesis and remodelling, especially the CL synthase CRLS1.

Previous studies focused on EAT gene expression either in patients with milder or no HF and compared subjects according to degree of left ventricular dysfunction or according to the presence of coronary artery disease. Expression of the genes characterized here remained either unaffected (LEP, TNFα; Fosshaug et al.12; and PLIN1, HSL, ATGL, ADIPOQ, LEP, IL6; Jaffer et al. 13) or only marginally changed (PPARα, IL6; Fosshaug et al.12). In this study, the overall pattern of EAT gene expression suggested simultaneous activation of lipolysis and lipogenesis in cachetic as compared with BW-stable HF-patients. Lipolysis was probably activated by the concert action of RAAS and sympathetic nervous systems and by natriuretic peptides.11,18 The prolipolytic factors contributing to cancer-related cachexia, CIDEA and zinc-α2-glycoprotein,26,36 were probably also involved. Activation of both lipolysis and energy dissipating fatty acid/triacylglycerol futile cycling in EAT is consistent with the high catabolic activity of adipose tissue and the overall catabolic dominance in HF-patients that was augmented further in association with adipose tissue wasting. Similar changes in adipose tissue metabolism were found in cancer cachexia.8,9 Presumably, the decrease in tissue triacylglycerol content due to increased lipolysis could not be compensated in full by activation of lipogenesis in EAT of cachetic patients. This is consistent with the effect of CL-induced uncoupling of oxidative phosphorylation in adipocytes when insufficient ATP production would limit several key biochemical activities engaged in triacylglycerols replenishment, such as gluconeogenesis, de novo synthesis of fatty acids and their re-esterification (Figure 7 and Supporting Information, Figure S3). Relatively high ADORA1 expression found in BW-stable patients grouped in Cluster A4 is typical of EAT, and ADORA1 up-regulation could contribute to the cardioprotection due to vasodilatation of coronary vessels.
and attenuation of β-adrenergic stimulation of lipolysis. However, in general, the changes in EAT gene expression in cachexia were only mild. It should be learned if they take place also in other fat depots, which differ in their metabolic features from EAT, and what is the contribution of the changes in adipose tissue metabolism to cardiac cachexia. For sure, due to its small mass, EAT plays an insignificant role in total energy balance.
Our study highlights the importance of the enhanced release of natriuretic peptides from the failing heart for the changes in EAT metabolism and development of cachexia as suggested by the higher levels of BNP in cachectic patients. Adipose tissue sensitivity to natriuretic peptides is regulated by NPRC and NPRC/NPRA ratio. Hence, the relatively low NPRC/NPRA ratio in the cachectic patients, resulting in enhanced bioavailability of natriuretic peptides in the EAT-myocardium microenvironment, could be important. In addition, a negative correlation was found between the expression of NPRC and levels of CL 70:6 in EAT (Spearman’s rank correlation coefficient = −0.561), supporting the role of NPRC in CL-induced changes of EAT metabolism in cachexia.

Comparisons between the subgroups of HF patients (i.e. BW-stable vs. cachectic, and Cluster A4 vs. Cluster B4 patients) revealed lower plasma BNP levels and higher daily doses of both β-blockers and ACE/ARB-inhibitors in the patients who were resistant to cachexia. These drugs prevent adverse neurohumoral activation that accompanies HF and, thus, represent the cornerstone of effective HF therapy, with their doses usually titrated to the maximally tolerated level. Therefore, HF patients who tolerated higher doses of these drugs were better protected against the development of cardiac cachexia. Indeed, β-adrenergic blockers and angiotensin II receptor antagonists have protective effects against fat loss due to cardiac cachexia (reviewed in Cabassi et al.). Anticachectic, adipose tissue-sparing effects of neurohumoral antagonist might therefore contribute to the favourable impact of these drugs on survival.

Our results support the idea that novel treatment strategies for HF-patients may be designed to target EAT metabolism and its secretory features, while changing EAT-myocardium microenvironment and, therefore, improving heart function. This could include neutralization of CIDEA activity to counteract excessive lipolysis in EAT, similarly as suggested for the treatment of cancer cachexia or inhibition of ATGL activity. Our findings here open a new possibility to treat cachexia by modulating CL biosynthesis and/or CL function. To this end, the use of cell-penetrating aromatic-cationic tetrapeptides that selectively target CL should be explored.

In conclusion, we observed here in patients with advanced HF that BNP signalling probably contributed to changes in EAT metabolome/lipidome and gene expression, reflecting dysregulated induction of EAT lipid metabolism in cardiac cachexia. Concomitant modulation of EAT-myocardium microenvironment may be involved in the deterioration of heart function in the cachectic patients. Our results suggest that the maintenance of stable BW and ‘healthy’ EAT-myocardium microenvironment of the HF-patients is associated with their ability to tolerate higher therapeutic doses of conventional therapeutics, namely neurohumoral inhibitors (ACE/ARB inhibitors and β-adrenergic blockers). We showed that induction of EAT levels of CL 70:6 could precipitate the wasting of adipose tissue. It is likely that an induction of minor CL species underlies energy dissipation in various tissues and represents one of the key events resulting in cachexia. Our results suggest that mitochondrial CL in EAT, as well as immunometabolic and secretory features of this tissue, could serve as a target for causal treatment of cardiac cachexia.

**Acknowledgements**

We would like to thank, Denisa Toulova, Petr Stavek, Regina Stupalova, and Nora Stankova for excellent technical assistance with this study. The authors certify that they comply with the ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2017.

**Conflict of interest**

None declared.

**Funding**

Ministry of Health (AZV ČR 17-28784A, AZV16-27496A and NV19-02-00118) and the project for the development of research organization 00023001 IKEM—institutional support.

**Online supplementary material**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Data S1. Method S1** Untargeted metabolomic and lipidomic analysis of EAT

**Table S1.** PCR primers

**Table S2.** Expression of selected genes in EAT

**Table S3.** Drugs and other non-physiological analytes in EAT extracts

**Table S4.** Cardiolipin and phosphatidylglycerol species levels in EAT

**Table S5.** Clinical variables, medication and plasma parameters in Cluster A4- and Cluster B4-patients

**Table S6.** Expression of selected genes involved in cardiolipin synthesis in EAT

**Figure S1.** Chemical classes of all the analytes with known structure detected in EAT.

**Figure S2.** Correlations between levels of CLs and PGs in EAT.
Figure S3. Induction of EAT lipid metabolism linked to cachexia – formation and role of CL.

Dataset S1. All 750 analytes with known structure detected in EAT extracts from HF-patients, including isobars.

Dataset S2. Analytes in EAT extracts with known structures and significantly different mean levels in (A) BW-stable and cachectic, and (B) Cluster A4- and Cluster B4-patients, respectively.

References

1. Kenchalaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LA, Skalli H, et al. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation 2007;116:627–636.

2. Horwich TB, Fonarow GC, Clark AL. Obesity and the obesity paradox in heart failure. Prog Cardiovasc Dis 2018;61:151–156.

3. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050–1053.

4. Melenovsky V, Kotrc M, Borlaga BA, Marek T, Kovar J, Malek I, et al. Relationships between right ventricular function, composition, and prognosis in advanced heart failure. J Am Coll Cardiol 2013;62:1660–1670.

5. Enk WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr 2008;27:793–803.

6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–957.

7. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003;361:1077–1083.

8. Rohm M, Zeigerer A, Machado J, Herzig S. Energy metabolism in cachexia. EMBO Rep 2019;20:472578.

9. Rohm M, Schafer M, Laurent V, Ustunel BE, Niopék K, Algire C, et al. An AMP-activated protein kinase-stabilizing peptide ameliorates adipose tissue wasting in cancer cachexia in mice. Nat Med 2016;22:1120–1130.

10. Halle JL, Pena GS, Paez HG, Castro AJ, Rossiter HB, Visavadiya NP, et al. Tissue-specific dysregulation of mitochondrial respiratory capacity and coupling control in colon-26 tumor-induced cachexia. Am J Physiol Regul Integr Comp Physiol 2019;317:R68–R82.

11. Szabo T, Postrach E, Mahler A, Kung T, Turhan G, von Haelhing S, et al. Increased catabolic activity in adipose tissue of patients with chronic heart failure. Eur J Heart Fail 2013;15:1113–1117.

12. Fosshaug LE, Dahl CP, Risnes I, Bohov P, Berge RK, Nymo S, et al. Altered levels of fatty acids and inflammatory and metabolic mediators in epicardial adipose tissue in patients with systolic heart failure. J Card Fail 2015;21:916–923.

13. Jaffer I, Riederer M, Shah P, Peters P, Quehenberger F, Wood A, et al. Expression of fat mobilizing genes in human epicardial adipose tissue. Atherosclerosis 2012;220:122–127.

14. Kintscher U, Foryst J, Malek I, Kautzner J, et al. Lipolytic effects of J Am Coll Cardiol 2013;61:1498–1507.

15. Rossiter HB, Visavadiya NP, et al. Tissue catabolic activity in adipose tissue. Atherosclerosis 2012;219:2360–2372.

16. Salatizki J, Foryst-Ludwig A, Haemmerle G, Zechner R. The role of adipose tissue ATGL lipase and cytosolic lipolysis in cardiac function and heart failure. Cell Rep Med 2020;1:1–21.

17. Packer M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. J Am Coll Cardiol 2015;67:1:923–930.

18. Moro C, Lafontan M. Natriuretic peptides and cGMP signaling control of energy homeostasis. Am J Physiol Heart Circ Physiol 2013;304:H538–H568.

19. Cabassi A, Coghi P, Barouhiel E, Moro C, Lafontan M. Natriuretic peptides in pressure and cGMP signaling control of energy homeostasis. Am J Physiol Heart Circ Physiol 2013;304:H538–H568.

20. Buresova J, Janovska P, Kuda O, Krizova J, der Stelt IR, Keijer J, et al. Postnatal induction of muscle fatty acid oxidation in mice differing in propensity to obesity: a role of pyruvate dehydrogenase. Int J Obes (Lond) 2018;44:235–244.

21. Funcke JB, Scherer PE. Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication. J Lipid Res 2019;60:1648–1684.

22. Dumas JF, Peyta L, Couet C, Servais S. Implication of liver cardiolipins in mitochondrial energy metabolism disorder in cancer cachexia. Biochimie 2013;95:27–32.

23. Chong J, Soufan O, Li C, Caraus I, Li S, Bourque G, et al. MetaMorphAnalyst 4.0: towards more transparent and integrative metabolomics analysis. Nucleic Acids Res 2018;46:W486–W494.

24. Wakai E, Aritaite K, Urade Y, Fujiwara K. Prostaglandin D2 enhances lipid accumulation through suppression of lipolysis via DP2 (CRTH2) receptors in adipocytes. Biochim Biophys Acta 2017;2007–2018;490:339–399.

25. Guaque-Clarte S, Gaudreault N, Piche ME, Fournier D, Mauriege P, Mathieu P, et al. The transcriptome of human epicardial, mediastinal and subcutaneous adipose tissues in men with coronary artery disease. PLoS One 2011;6:e19908.

26. Mrange M, Stephens NA, Gao D, Bao Y, Ross JA, Ryden M, et al. Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients. Br J Cancer 2011;104:441–447.

27. Masoodi M, Kuda O, Rossmeisl M, Flachs P, Kopecky J. Lipid signaling in adipose tissue: connecting inflammation & metabolism. Biochim Biophys Acta 1851;2015:503–518.

28. Buresova J, Janovska P, Kuda O, Krizova J, der Stelt IR, Keijer J, et al. Postnatal induction of muscle fatty acid oxidation in mice differing in propensity to obesity: a role of pyruvate dehydrogenase. Int J Obes (Lond) 2018;44:235–244.

29. Funcke JB, Scherer PE. Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication. J Lipid Res 2019;60:1648–1684.

30. Dumas JF, Peyta L, Couet C, Servais S. Implication of liver cardiolipins in mitochondrial energy metabolism disorder in cancer cachexia. Biochimie 2013;95:27–32.

31. Julienne CM, Tardieu M, Chevalier S, Pinault M, Bougnoux P, Labarthe F, et al. Cardiolipin content is involved in liver mitochondrial energy metabolism associated with cancer-induced cachexia without the involvement of adenine nucleotide translocase. Biochim Biophys Acta 2014;1842:726–733.

32. Schlame M, Rua D, Greenberg ML. The biosynthesis and functional role of cardiolipin. Prog Lipid Res 2000;39:257–288.

33. Saini-Chohan HK, Mitchell RW, Vaz FM, Zelinski T, Hatch GM. Delineating the role
of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: thematic review series: genetics of human lipid diseases. *J Lipid Res* 2012;**53**:4–27.

35. Li J, Romestaing C, Han X, Li Y, Hao X, Wu Y, et al. Cardiolipin remodeling by ALCAT1 links oxidative stress and mitochondrial dysfunction to obesity. *Cell Metab* 2010;**12**:154–165.

36. Zhu HJ, Ding HH, Deng JY, Pan H, Wang LJ, Li NS, et al. Inhibition of preadipocyte differentiation and adipogenesis by zinc-alpha2-glycoprotein treatment in 3T3-L1 cells. *J Diabetes Investig* 2013;**4**:252–260.

37. Rognstad R, Katz J. The effect of 2,4-dinitrophenol on adipose-tissue metabolism. *Biochem J* 1969;**111**:431–444.

38. Rossmeisl M, Syrovy I, Baumruk F, Flachs P, Janovska P, Kopecký J. Decreased fatty acid synthesis due to mitochondrial uncoupling in adipose tissue. *FASEB J* 2000;**14**:1793–1800.

39. Szeto HH, Liu S. Cardiolipin-targeted peptides rejuvenate mitochondrial function, remodel mitochondria, and promote tissue regeneration during aging. *Arch Biochem Biophys* 2018;**660**:137–148.

40. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2019. *J Cachexia Sarcopenia Muscle* 2019;**10**:1143–1145.